PDCD1 and esophageal cancer: Currently, in clinical trials or studies of neoadjuvant immunotherapy combined with chemotherapy for esophageal cancer, PD-1 inhibitors involved include pembrolizumab, sintilimab, camrelizumab, tislelizumab, toripalimab, and nivolumab.